- Home
- NUVB vs RYN Comparison
NUVB vs RYN Comparison
Compare NUVB & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVB | RYN |
|---|---|---|
| Founded | 2018 | 1926 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUVB | RYN |
|---|---|---|
| Price | $8.47 | $21.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $10.63 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 10.3M | 1.3M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 13.13% |
| EPS Growth | N/A | ★ 373.89 |
| EPS | N/A | ★ 5.07 |
| Revenue | $26,748,000.00 | ★ $1,293,371,000.00 |
| Revenue This Year | $609.55 | N/A |
| Revenue Next Year | $197.91 | N/A |
| P/E Ratio | ★ N/A | $4.34 |
| Revenue Growth | ★ 1137.19 | 60.70 |
| 52 Week Low | $1.54 | $21.06 |
| 52 Week High | $8.95 | $31.09 |
Technical Indicators
Market Signals| Indicator | NUVB | RYN |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 44.44 |
| Support Level | $7.80 | $21.24 |
| Resistance Level | $8.95 | $22.85 |
| Average True Range (ATR) | 0.51 | 0.54 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 74.78 | 27.63 |
Price Performance
Historical ComparisonAbout NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.